Shield Therapeutics

Shield Therapeutics is a commercial-stage biopharmaceutical company with a focused mission to address the significant unmet needs in iron deficiency anemia (IDA) through differentiated oral therapies. Its core achievement is the development and U.S./EU approval of Accrufer/Feraccru (ferric maltol), a novel, non-salt-based iron chelate designed for improved GI tolerability and absorption. The company's strategy revolves around maximizing the commercial potential of Accrufer through targeted commercialization, label expansion into new patient populations, and lifecycle management. Shield operates as a lean, specialized organization, transitioning from an R&D entity to a commercial player in the global hematology market.

Specialized expertise in iron metabolism and chelation chemistry, embodied in its patented ferric maltol compound—a non-salt-based chelate designed for improved gastrointestinal tolerability and absorption via alternative pathways.